- ￥2262
- LSM Bio
- 进口
- PAab03164
- 2025年07月09日
- ELISA,WB,IP
- E. coli - derived recombinant protein
- Human,Mouse ,Rat
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
fms-related tyrosine kinase 3
- 亚型：
IgG
- 形态：
liquid
- 保存条件：
负20摄氏度
- 克隆性：
Polyclonal antibody
- 标记物：
Non-conjugated
- 适应物种：
Human,Mouse ,Rat
- 保质期：
6个月
- 抗原来源：
Rabbit
- 目录编号：
Q9WVH4
- 级别：
纯化级别
- 库存：
50
- 供应商：
LSM bio
- 宿主：
E. coli - derived recombinant protein
- 应用范围：
ELISA,WB,IP
- 浓度：
≥95% as determined by SDS-PAGE
- 靶点：
FLT3
- 抗体英文名：
anti-FLT3 antibody,FLT3 antibody
- 抗体名：
anti-FLT3 抗体,FLT3 抗体
- 规格：
100μl
FLT3抗体| FLT3 antibody
货号 PAab03164
蛋白别名 CD135 antibody, FLK2 antibody, STK1
蛋白介绍
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
产品描述
anti-FLT3 antibody is a Rabbit Polyclonal antibody againstFLT3..
建议稀释比例
IHC
Western blot
(本抗体仅供体外科研用途，不可用于临床诊断!)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验FLT3 Mutations in Acute Myeloid Leukemia
The prevalence of an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence and a missense mutation of D835 within the kinase domain of the FLT3 gene is 15–35% and 5–10% of adults with acute myeloid leukemia (AML
Molecular Genetic Tests for FLT3, NPM1, and CEBPA in Acute Myeloid Leukemia
in FLT3 (FMS-like tyrosine kinase 3), NPM1 (Nucleophosmin), and CEBPA (CCAAT/enhancer-binding protein alpha) genes hold prognostic significance in patients with AML and normal cytogenetics. Therefore, mutation identification may help to optimize
of this phenomenon. Our approach is based on immunoprecipitation of the protein of interest on the surface of beads, followed by detection of the protein or its modification (phosphorylation) using a secondary antibody labeled with phycoerythrin at a 1∶1 ratio. Fms
技术资料暂无技术资料 索取技术资料
